Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 65.55
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very poor margins and returns
Data is available to registered users only
Data is available to registered users only
About
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of ORKA is 52 and suggests 22% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
Data is available to registered users only
Buy
Sell